InfuCare Rx®

Immune Globulin Neurology Enrollment Form

Fax Referral To: 877-828-3941
Phone: 877-828-3940
referrals@infucarerx.com
www.infucarerx.health

Please cut along the dotted lines before submitting to a pharmacy.

Date Required: _____ Ship To: ☐ Patient ☐ MD Office ☐ Other: _____

PATIENT INFORMATION

Patient Name: _____
Address: _____
City, State, Zip: _____
Home Phone: _____
Cell Phone: _____
Date of Birth: _____ Gender: _____
Emergency Contact: _____ Phone: _____

PRESCRIBER INFORMATION

Prescriber Name: _____
Address: _____
City, State, Zip: _____
Phone: _____
Fax: _____
DEA #: _____ NPI #: _____
Contact Person: _____

INSURANCE INFORMATION (Please attach the front and back of insurance and prescription drug card.)

Primary Insurance: _____ ID: _____ Group: _____
Secondary Insurance: _____ ID: _____ Group: _____
Prescription Card: _____ ID: _____ BIN: _____ PCN: _____

To better serve your patient and facilitate insurance authorization, please complete the pertinent sections:

DIAGNOSIS

☐ G13.0 Paraneoplastic syndrome
☐ G25.82 Stiff-Person syndrome
☐ M33.10 Dermatomyositis
☐ M33.22 Polymyositis
☐ G35.A Relapsing-remitting multiple sclerosis
☐ G35.B0 Primary progressive multiple sclerosis, unspecified
☐ G35.B1 Active primary progressive multiple sclerosis
☐ G35.B2 Non-active primary progressive multiple sclerosis
☐ G35.C0 Secondary progressive multiple sclerosis, unspecified
☐ G35.C1 Active secondary progressive multiple sclerosis
☐ G35.C2 Non-active secondary progressive multiple sclerosis
☐ G35.D Multiple sclerosis, unspecified
☐ G61.0 Guillain-Barré syndrome
☐ G61.81 Chronic inflammatory demyelinating polyneuropathy (CIDP)
☐ G61.82 Multifocal motor neuropathy (MMN)
☐ G70.01 Myasthenia gravis w/acute exacerbation
☐ G70.80 Lambert-Eaton syndrome
☐ Other: _____

PATIENT EVALUATION

Has patient previously received IVIG? ☐ Yes ☐ No
Patient Weight: _____ ☐ kg ☐ lbs Height: _____ ☐ cm ☐ in
Allergies: _____
Line Access: ☐ Peripheral ☐ PICC ☐ Port
Delivery Method: ☐ Infusion Pump ☐ Other: _____
Therapy Start Date: _____ Therapy End Date: _____
Injection Training/Home Health RN visit is necessary. ☐ Yes ☐ No
☐ Home ☐ MD Office ☐ Other: _____

☐ Patient demographics, including insurance information.
☐ Labs – Antibody testing results, most recent BUN/SCr and IgA level
☐ H&P
☐ Medications tried and failed: _____
☐ Baseline assessment, including detailed patient symptoms
☐ Please attach original prescription orders

As Appropriate:
☐ Nerve Conduction Study results, including velocities
☐ Biopsy results
☐ Electromyography (EMG) results
☐ CSF studies

☐ Other: _____

PRESCRIPTION INFORMATION

Immune Globulin Prescription (IVIG):

Loading Dose: IVIG _____ gm/kg given over _____ day(s) OR _____ gm daily for _____ day(s)

Maintenance: IVIG _____ gm/kg given over _____ day(s) OR _____ gm daily for _____ day(s)

☐ Repeat course every _____ week(s) x _____ course(s). Refill x 1yr.

Subcutaneous Immune Globulin Prescription (SCIG):

SCIG _____ gm monthly OR _____ gm every _____ weeks. Refill x 1yr.
☐ Pharmacy to select number of infusion sites OR ☐ Administer with _____ needle sites

☐ OK to round to the nearest vial size
☐ +/- 4 days to allow scheduling flexibility

Multiple doses will be administered on consecutive days unless ordered otherwise.
☐ non-consecutive days only

PREMEDICATION ORDERS/OTHER MEDICATIONS

Flush Protocol
☐ NaCl 0.9% 5mL
☐ NaCl 0.9% 10mL
☐ Heparin 10 units per mL
☐ Heparin 100 units per mL
☐ 250mL 0.9% NaCl for hydration
☐ Other: _____

Premedications & Other Medications
☐ Infusion supplies as per protocol
☐ Anaphylaxis Kit orders as per protocol
☐ Acetaminophen _____ mg PO prior to infusion
☐ Diphenhydramine _____ mg PO

Prescriber Signature: _____ **Date:** _____

The information contained in this facsimile may be confidential and is intended solely for the use of the named recipient(s). Access, copying or re-use of the facsimile or any information contained therein by any other person is not authorized. If you are not the intended recipient, please notify us immediately by faxing back to the originator.

Revised 05 October 2026